Popular Stories

Drug Tag

  • All
  • Biotechnology
  • Cannabis
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Initiates Make-or-Break Phase 3 Clinical Trials in AngelMan Syndrome

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company developing novel therapeutics for rare neurological disorders, announced the launch of a crucial phase 3 clinical trial in Angelman Syndrome named NEPTUNE. OV101, its lead candidate for  the treatment of syndrome and Fragile X Syndrome is a delta-selective...

New Drugs show promise in curbing the Gonorrhea Menace

Gonorrhoea, caused by a bacterial pathogen N. gonorrhoea, is the second most commonly reported sexually transmitted disease in the U.S alone. The data made available by Centres for Disease Control and Prevention (CDC) shows that in 2017, a total of 555,608 cases of gonorrhoea were reported...

WordPress Video Lightbox Plugin